You are here

Cost Effectiveness Of Linezolid In Central America

Last updated on April 10, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ventilator Acquired Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a legally acceptable representative signed and dated informed consent
document indicating that him or her has been informed of all pertinent aspects of the
study.

- Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on
ICU with LIN or VAN; on the selected institutions.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Adult men or women with nosocomial pneumonia not associated to a ventilator.

NCT01040585
Pfizer
Withdrawn
Cost Effectiveness Of Linezolid In Central America

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
NCT03329092
All Genders
18+
Years
Multiple Sites
Pneumonia, Meningitis, Bacteremia, Sepsis
NCT00428051
All Genders
0+
Years
Multiple Sites
Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia
NCT01561469
All Genders
Community Acquired Infections
NCT00488397
All Genders
0+
Years
Taipei, Taiwan
Cost Effectiveness Of Linezolid In Central America
Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Adult men and women with VAP.
Ventilator Acquired Pneumonia
Drug: Linezolid
Treatment for VAP as indication approved and as physician criterium.
Central America and the Caribbean
Panama, Costa Rica, Honduras, El Salvador and Nicaragua
Intervention: Drug: Linezolid
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
March 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study.
  • Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions.

Exclusion Criteria:

  • Adult men or women with nosocomial pneumonia not associated to a ventilator.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
El Salvador,   Honduras,   Nicaragua
 
NCT01040585
A5951154
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now